GSK has acquired worldwide rights to an oral non-nucleoside reverse transcriptase inhibitor, IDX899, from Idenix Pharmaceuticals. The anti-HIV drug has increased drug resistance and higher potency, which is hoped would combat the increasing prevalence of viral resistance and side effects associated with this class of drugs.